Despite Risks, Antipsychotic Polypharmacy on the Rise

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Antipsychotic polypharmacy has risen globally over 50 years even though the practice is linked to worse outcomes, more side effects, and increased all-cause mortality.
Medscape Medical News